Thelansis

Spinal Muscular Atrophy (SMA) Market Access and Reimbursement Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would imp...

Spinal Muscular Atrophy (SMA) Epidemiology Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies. Key business questions answered: 20-year historical and forecast data (2020–2040) Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes) Granular patient population coverage by year and geography Detailed segmentation by age, gender, subpopulations, comorbidities, line...

Spinal Muscular Atrophy (SMA) Emerging Therapy and TPP Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product...

Spinal Muscular Atrophy (SMA) Current Treatment Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Current Treatment Insights Report – 2025″ describes the current treatment and management in Alzheimer’s Disease. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted. Key business questions answered: Patient characteristics/patient segments Patient diagnosis criteria Patient shares for current therapies Line of therapy analysis Treatment sequencing Patient journey Compliance and persistency analysis Polypharmacy Factors impacting physician choice of treatments Driv...

Spinal Muscular Atrophy (SMA) Market Outlook Thelansis’s “Spinal Muscular Atrophy (SMA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Spinal Muscular Atrophy (SMA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on t...

Spinal Muscular Atrophy (SMA) Market Access and Reimbursement Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder primarily characterized by the progressive, irreversible loss and degeneration of alpha motor neurons in the anterior horn of the spinal cord and brain stem, leading to profound, typically symmetric, muscle weakness and atrophy, most severely affecting the proximal muscles and eventually causing paralysis in severe cases. This condition is overwhelmingly ...

Spinal Muscular Atrophy (SMA) Epidemiology Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies. Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder primarily characterized by the progressive, irreversible loss and degeneration of alpha motor neurons in the anterior horn of the spinal cord and brain stem, leading to profound, typically symmetric, muscle weakness and atro...

Spinal Muscular Atrophy (SMA) Emerging Therapy Thelansis’s “Spinal Muscular Atrophy (SMA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder primarily characterized by the progressive, irreversible loss and degeneration of alpha motor neurons in the anterior horn of the spinal cord and brain stem, leading to profound, typically symmetric, muscle weakness and atrophy, most severely affecting the proximal muscles and eventually causing paralysis in severe cases. This condition is overwhelmingly caused by mutations or deletions in the Survival Motor Neuron 1 ( SMN1 ) gene, which results in a deficiency of the cr...

Spinal Muscular Atrophy (SMA) Current Treatment Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Current Treatment Insights Report – 2025″ describes the current treatment and management in Alzheimer’s Disease. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted. Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder primarily characterized by the progressive, irreversible loss and degeneration of alpha motor neurons in the anterior horn of the spinal cord and brain stem, leading to profound, typically symmetric, muscle weakness and atrophy...

  Spinal Muscular Atrophy (SMA) Market Outlook Thelansis’s “Spinal Muscular Atrophy (SMA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Spinal Muscular Atrophy (SMA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is characterized by the degeneration of alpha motor neurons in the anterior horn cells of the spinal cord, leading to progressive weakness and wasting of proximal muscles and, in severe cases, paralysis. The clinical presentation of SMA varies from severe to mild. It is classified into three subtypes: type I (also known as Werdnig-Hoffman disease),...

 Spinal muscular atrophy (SMA) is characterized by the degeneration of alpha motor neurons in the anterior horn cells of the spinal cord, leading to progressive weakness and wasting of proximal muscles and, in severe cases, paralysis. The clinical presentation of SMA varies from severe to mild. It is classified into three subtypes: type I (also known as Werdnig Hoffmann disease), type II, and type III (also referred to as Kugelberg Welander disease), as well as type IV. This condition involves muscle weakness and atrophy due to progressive degeneration and irreversible loss of lower motor neurons in the spinal cord and brain stem nuclei. The onset of weakness can occur from prenatal stages to adulthood, typically displaying a symmetric, proximal > or distal pattern that worsens over time. Previously, SMA was categorized into clinical subtypes based on the maximum motor function achieved; however, it is now understood that the phenotype of SMN1-associated SMA exists along a conti...

 Spinal muscular atrophy (SMA) is characterised by degeneration of the alpha motor neurons of the anterior horn cells of the spinal cord, resulting in progressive proximal muscle weakness and atrophy and, in the most severe types, paralysis. The clinical phenotype of SMA is heterogeneous, ranging from severe to mild. It is classified into three subtypes: type I (also known as Werdnig Hoffmann disease), type II, and type III (also called Kugelberg Welander disease). ·        The estimated prevalence of spinal muscular atrophy (SMA) in the USA ranges between 9 to 10 cases per 100,000 population. However, the incidence cases range between 1.2 to 1.5 cases per 11,000 live birth population. Thelansis’s “Spinal Muscular Atrophy (SMA) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice,...

  Spinal muscular atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. Etiology- SMA types 0, 1, 2, 3, and 4 are inherited as autosomal recessive genetic disorders and are associated with abnormalities (mutations) in the SMN1 and SMA2 genes on chromosome 5 at chromosomal locus 5q11-q13. SMA1 is thought to be the primary disease-causing gene. Epidemiology- Spinal muscular atrophy affects 1 per 8,000 to 10,000 people worldwide. The competitive landscape of Spinal muscular atrophy (SMA) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Spinal muscular atrophy (SMA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment land...